Group 1 - The company views the pet pharmaceutical sector as one of its key development directions and is optimistic about its future prospects [2] - The company has adjusted resource allocation to increase investment in pet pharmaceutical research and market channel development [2] - The company has established an independent and specialized research team for pet pharmaceuticals and has obtained seven product approvals in the first half of the year, significantly expanding its product line [2] Group 2 - The company's pet pharmaceutical products mainly cover various subfields, including antiparasitics, analgesics, dermatological medications, internal medicine, and functional health products [2]